Clovis Oncology Inc. Stock
€0.68
Your prediction
Clovis Oncology Inc. Stock
Pros and Cons of Clovis Oncology Inc. in the next few years
Pros
Cons
Performance of Clovis Oncology Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Clovis Oncology Inc. | -4.040% | -9.860% | -66.189% | -84.301% | -71.810% | -95.482% | -98.555% |
Epizyme Inc. | 1.410% | -2.400% | -29.784% | -93.131% | -78.243% | - | - |
Pieris Pharmaceuticals Inc | -0.140% | 4.332% | -40.580% | 12.709% | -42.353% | - | - |
Capricor Therapeutics Inc | 1.220% | 18.766% | 12.931% | 4.088% | 27.308% | - | - |
Comments
News

Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday

Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2022, and provided an update on the Company’s clinical development programs and regulatory and

Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that seven abstracts from the company’s pipeline, including late-breaking data from the ATHENA-MONO Phase 3 clinical trial evaluating Rubraca